trending Market Intelligence /marketintelligence/en/news-insights/trending/zfgk8p4ntovmrlmy0fbgtg2 content esgSubNav
In This List

Corcept Therapeutics plans $100M share buyback program

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Corcept Therapeutics plans $100M share buyback program

Corcept Therapeutics Inc. said its board approved the repurchase of up to $100 million of the company's common stock.

The Menlo Park, Calif.-based pharmaceutical company said the share buyback program will remain in effect until June 30, 2019, unless terminated earlier.

Corcept added that the timing and amount of any repurchases will be based on market conditions, stock price and other factors.